Termination of a Material Agreement (Entry/Termination)

Analyst Summary

Outlook Therapeutics closed a $33.1 million unsecured convertible promissory note with Avondale Capital, LLC, and used the proceeds to fully repay its existing debt of $32,910,027.57 to Streeterville Capital, LLC.
The company’s stockholders approved an amendment to the Restated Certificate of Incorporation to increase the authorized number of common stock shares from 60,000,000 to 260,000,000.
At the Annual Meeting, stockholders elected Julian Gangolli, Ralph H. “Randy” Thurman, and Lawrence A. Kenyon to serve as Class III directors until the 2028 Annual Meeting.
Stockholders approved the potential issuance of common stock exceeding 19.99% upon conversion of the new convertible note, even if the conversion price is below the Nasdaq minimum price.
KPMG LLP was ratified as the company’s independent registered public accounting firm for the fiscal year ending September 30, 2025.
A non-binding advisory vote on the compensation of the Company’s named executive officers was approved.